Red And White Vaccine Starts Production In Mid-2022

Screenshot of a media briefing held at the Coordinating Ministry for Human Development and Culture in Jakarta, Wednesday (29/12/2021). (ANTARA/Indriani)

JAKARTA - Head of the Food and Drug Supervisory Agency (BPOM) Penny Lukito said his party is targeting the Red and White vaccine to be produced in the middle or second semester of 2022.

"The Red and White Vaccine in collaboration with Universitas Airlangga and PT Biotis is currently in the production stage for clinical trials and clinical trials will soon be carried out. Production is targeted in the second half of 2022," said Penny at a media briefing in Jakarta, reported by Antara, Wednesday, December 29.

Likewise with other domestic COVID-19 vaccines, namely the cooperation vaccine of Bio Farma and Baylor College Medicine which is also targeted to be produced in the second semester of 2022. For the booster vaccine, Penny said that her party will immediately issue an emergency use permit or EUA. Currently in the registration process, namely Pfizer, AstraZeneca, Zlifivax and CoronaVac or Bio Farma's COVID-19 vaccine. While the new one is at the pre-registration stage, namely the Sinopharm vaccine.

Meanwhile, for the use of drugs that have been issued by BPOM, namely Favipiravir, Remdesivir and Regdanvimab. For emergency use permits for primary dose vaccines that have been issued for ages 6 to 11 years, namely Coronavac and Bio Farma. While those over 12 years old are Pfizer vaccines and those over 18 years old are eight vaccines, namely Astrazeneca, Moderna, Sputnik, Janssen, Convidecia, Zlifivax, Covovax, and the SARS COV2 KF vaccine.

"After the issuance of the emergency use permit, we carry out post-market surveillance to ensure compliance with the proper distribution of drugs, as well as the pharmacovigilance of post-immunization follow-up events or AEFIs," he explained again.*